This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Are Achillion, Inovio Buyout Targets, Like Merck's Idenix?: StockTwits

NEW YORK (TheStreet) -- Investors are betting on which company will be the next Idenix  (IDIX) -- a hot target for a buyout. The favorites on StockTwits.com? Achillion Pharmaceuticals  (ACHN) and Inovio  (INO).

Drug giant Merck  (MRK) announced Monday that it would acquire Idenix for $3.85 billion. The company's "promising portfolio" of hepatitis C treatments was the main driver of the deal, according to Merck's Research Laboratories president.

Many investors speculate that the $24.50 per share cash deal -- a more than 233% premium over the prior closing price -- was so high because of a bidding war with Merck competitors. And they believe the losing bidders -- reportedly Johnson & Johnson  (JNJ) and Abbvie  (ABBV) -- could now try to secure Idenix competitors with promising hep C drugs of their own.

$MRK need not have paid 4x the share price for $IDIX...Bidding war is absolutely active behind the scenes. $ACHN and $IDIX pretty similar. ? Golden Gate Sings (@goldengatesings2) Jun. 10 at 12:12 PM

$ACHN Abbvie and J&J are currently completely locked out of the Hep C market....ACHN will get its premium is my bet. ? Golden Gate Sings (@goldengatesings2) Jun. 10 at 12:11 PM

Achillion Pharmaceuticals has several Hepatitis C treatments in human trials. The company announced today that it began dosing patients with chronic hepatitis C with its ACH-3422 drug and will report the results in the fall. It also announced that the FDA removed a clinical hold on sovaprevir, another hepatitis C treatment. Sovaprevir is in Phase 2 clinical trials and can resume dosing patients with hepatitis C. The company can also dose some healthy control patients, but not as many times, according to the FDA.

The stock surged more than 53% after the news.

All the A named bios came back from FDA adversity $ARIA $ACHN next is $AFFY if drug comes back upside over 1,000% ? So Generous (@sogenerous) Jun. 10 at 12:12 PM

Inovio Pharmaceuticals also has several hepatitis vaccines, also known as immunotherapies. It has a hepatitis C vaccine in Phase 1 human trials and a hepatitis B vaccine in preclinical trials. The company's pipeline also includes vaccines for HIV, influenza, malaria and HPV strains that cause cervical cancer and head and neck cancers.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ACHN $10.05 -2.05%
IDIX $24.50 0.20%
AAPL $127.60 2.28%
FB $83.09 2.87%
GOOG $535.38 2.16%

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs